Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria:

• Diagnosed with cancer, stage 1-4.

• Completed taxane- or platinum-based chemotherapy, vinca alkaloids, or bortezomib atleast three months (90 days) ago. Current use of anti-estrogen therapy, Herceptin,or PARP inhibitors is okay.

• Clinical diagnosis of chemotherapy-induced peripheral neuropathy by clinician. Thiswill be based on symptom history (paresthesias, dysesthesias, allodynia), loss ofdeep tendon reflexes, decreased vibratory sensation, or the presence of symmetricalstocking-glove numbness or paresthesias beginning after neurotoxic chemotherapy.

• Self-reported average neuropathic pain score of at least 4 on a 10-point scale overthe past 1 month.

• Age ≥ 18 years

• Concomitant use of analgesics is permitted if the dose has been stable for at least 2 weeks prior to study enrollment (no new analgesics have been added, discontinued,or changed in the 2 weeks prior to randomization).

• Written informed consent obtained from subject and ability for subject to complywith the requirements of the study.

Exclusion Criteria:

• Syphilis, alcoholic neuropathy, diabetic neuropathy, neurological disorders, braininjury, or stroke, as assessed by the treating physician.

• Neuropathy related to abnormal thyroid stimulating hormone or cobalamin levels asassessed by treating physician.

• Current severe depression, suicidal ideation, bipolar disease, alcohol abuse, ormajor eating disorder, as assessed by the treating physician.

• Currently participating in another chemotherapy-induced peripheralneuropathy-targeted program or trial.

• Participated in a non-pharmacologic therapy specifically for the treatment ofchemotherapy-induced peripheral neuropathy, including Scrambler Therapy, mindfulnessmeditation, or other mind-body activities within 14 days (2 weeks) prior torandomization.